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The physiologic function of fetal hyperglucagonemia is also open to question. A hyperglycemic response to pharmacologic injection has been suggested in in vivo preparations (6) . In order to clarify the role of glucagon as a possible fetal metabolic regulatory hormone, we utilized the chronically catheterized fetal sheep as our model. Varying degrees of hyperglucagonemia were induced and alterations in fetal glucagon, insulin, glucose and ketone concentrations as well as umbilical glucose and ketone uptakes then noted.
Summary Speculation
The fetus in late gestation may respond to substrate deprivation by secretion of glucagon. If so, a modest but significant hyperglycemia would result, presumably the result of acute fetal glycogenolysis. The acute fetal metabolic adaptation to maternal starvation, however, if modified by glucagon, does not include utilization of ketones as alternate substrates.
Acute glucagon injections were performed in chronically catheterized fetal lambs in late gestation to assess the fetal metabolic response to exogenous glucagon infusion. Glucagon dosages between 1 p,g/kg and 1 mg/kg induced significant fetal hyperglycemia by 15-30 min postinjection, with peak glucose values 130-180% of control. Increasing responsivity to the same dose/kg was noted to parallel increasing gestational age. In selected preparations in which umbilical venous catheters were implanted, glucagon injection caused an acute fall in the glucose/oxygen quotient and net umbilical glucose consumption. The fall in glucose consumption to 8% of control values occurred within 15 min of injection and suggests acute fetal glucose excretion, probably secondary to hepatic glycogenolysis. Glucagon injection in the neonatal lamb caused qualitatively similar increases in plasma glucose concentration but the quantitative responses were considerably greater. No change in fetal ,B-hydroxybutyrate (,B-ORD) concentration was noted after injection; nor did the fetal uptake or excretion of this ketone change. The neonatal ,B-ORD concentration was significantly different (P < 0.001) from fetal concentrations and did rise 14% above control after glucagon injection; thus, elevation of plasma glucagon in the fetus causes an acute hyperglycemia but, unlike the adult, does not induce a significant ketogenesis.
Experimental design. Eleven pregnant ewes between 118-149 days of gestation were studied (Table 1) . Term gestation in the sheep is 147 days. All but two had singleton fetuses. Intravenous sodium pentobarbital and spinal anesthesia were administered to each animal preoperatively. Polyvinyl catheters were then placed in a fetal pedal artery and vein as well as the maternal femoral artery for purposes of sampling and infusion. In five of the fetal lambs umbilical venous catheters were also implanted. All catheters were then tunneled subcutaneously to a pouch on the mother's flank. Postoperative care and feeding were performed as previously described (22) . Experiments were not performed until after a 4-day recovery period.
A total of 26 glucagon injections were performed in the experimental animals. When serial injections were performed, the dosages were administered in random order and at least 48 h separated exposure to exogenous glucagon. Crystalline beef/pork glucagon (33) dissolved in normal saline was injected by hand in a pedal Elevation of circulating plasma glucagon occurs in the adult in vein over 1 min. Dosages ranged from 0.001-1.0 mg/kg estimated response to stimuli such as hypoglycemia, fasting or certain chemfetal weight. Radioimmunoassayable insulin was measured in ical secretogogues such as alanine or arginine (29) . Ryperglucaseveral lots of glucagon solution injected. Maximum insulin congonemia, due to either endogenously released glucagon or exogecentration determined was 120 p.U/mi. At the highest dose of nous infusion, is associated with an immediate hyperglycemic glucagon utilized (1.0 mg/kg) this would cause a maximum eleresponse (9, 29) . Although the glycogenolytic and gluconeogenic vation of 0.2 p.U/ml in fetal plasma. effects of glucagon upon hepatic glucose production are well
Fetal arterial blood for determination of plasma glucose conknown (29) , it has also recently been suggested that glucagon centration was withdrawn 2-3 times during the hour before injecsecretion may play an important role in the normal regulation of tion and then at 15, 30, 60, 90, and 120 min postinjection. Due to hepatic glucose production in the resting state (19) . In addition, limitations placed upon the amount of fetal blood withdrawn, ketogenic effects of glucagon stem from this hormone's ability to however, only selected samples for determination of ,B-hydroxyinduce lipolysis and to stimulate hepatic fatty acid oxidation (5, butyrate (II experiments), glucagon (10 experiments), and insulin 32); thus, glucagon secretion in the adult promotes the utilization (16 experiments) were available. Maternal arterial glucose, insulin, of endogenous substrates for energy purposes, especially in times and glucagon concentrations were also assessed during control of stress.
and experimental periods to detect any alterations in maternal Whether or not the mammalian fetus secretes glucagon in homeostasis. In experiments done on the fetal lambs with umbilresponse to appropriate stimuli is controversial. Neither Chez and ical venous catheters in place, fetal arterial and umbilical venous co-workers (7) nor Fiser et al. (11) were able to document changes blood samples were withdrawn simultaneously and analyzed for in fetal glucagon concentration in primate or sheep fetuses, rewhole blood oxygen contents, plasma glucose concentrations, and spectively, in response to a variety of stimuli. Other investigators whole blood glucose and ,B-ORB concentrations. Arterial plasma Maternal control glucagon concentration was 295 ± 118 pg/ml and did not change significantly after fetal glucagon injection. Similarly, no changes in maternal glucose or insulin concentrations were noted during the course of the experiments. Fetal control glucagon concentration was 159 ± 24 pg/ml, not significantly different from maternal control values. Neonatal lamb control glucagon concentrations (208 ± 21 pg/ml) were above the mean fetal level but, although a trend was evident, the difference was not significant (P < 0.07). The mean fetal volume of distribution (Vd) and halflife (t%) for glucagon were similar over the range of dosages utilized (0.001-1.0 mg/kg) in complete kinetic studies. A representative example is shown in Figure 1 . All decay curves were best described by a two compartment kinetic model.
Mean fetal Vd and t% for the pooled experiments were 505 ± 107 ml/kg and 79 ± 21 min, respectively. In general, fetal glucagon injections of 0.1 mg/kg and above yielded initial fetal glucagon concentrations in excess of 0.5 JLg/ml, or approximately 5000-fold above physiologic concentrations. Dosages of 1-10 JLg/kg were associated with proportionately lower peak concentrations of glucagon (Fig. 2) .
No changes were noted in fetal blood gases, hematocrit, or blood pressure during the glucagon injection experiments. Basal plasma glucose was 24.7 ± 1.3 mg/dl. Significant elevations in plasma glucose were noted at 15 and 30 min postinjection at all glucagon doses utilized (P < 0.05). Results were converted to % change from baseline in order to minimize interanimal variability (Fig. 3 ). Peak elevation occurred by 30 min postinjection and ranged from 130-180% of basal plasma glucose concentration. Although the decline in glucose concentrations from 60-120 min differed between doses, the peak responses to doses of 0.01-1.0 mg/kg glucagon were statistically similar. At a dosage of 1 JLg/kg, plasma glucose rose less than at higher doses (P < 0.05), reaching 29 ± 13 and 32 ± 18% above baseline concentrations (P < 0.02) at IS and 30 min, respectively (Fig. 3) . In selected experiments fetal glucose response to the same glucagon dose/kg (adjusted for increasing fetal weight) was assessed at different gestational ages. A trend toward increasing responsivity to glucagon with advancing gestational age was evident. Sufficient data from injections at different gestational ages were available (0.01-0.1 mg/kg glucagon) to contrast peak glucose response with gestational age (Fig.  4) . Linear regression analysis delineated a significant relationship (P < 0.02) between advancing gestational age and degree of fetal hyperglycemia. Figure 5 depicts the changes in the venoarterial difference of whole blood glucose and glucose/02 quotients after glucagon in the fetal lambs in which umbilical venous catheters were im-RESULTS PHILIPPS ET AL.
zymatically utilizing 3-hydroxybutyrate dehydrogenase (31) . Antipyrine concentration was measured using the Technicon Autoanalyzer.
Glucagon radioimmunoassay was performed using a modification of Unger's technique (10) with the antibody 30K and [ 125 1]_ glucagon. A double antibody separation method (16) was used with goat anti-rabbit gamma globulin. Insulin radioimmunoassay utilized a double antibody separation method (16) and ovine insulin standards (33) . Blood for glucagon and insulin assays were treated immediately with a mixture of 10 U heparin/500 K.I.U. Trasylol (34) per I ml sample, centrifuged and the supernatant then stored at -70°C until time of assay.
Statistical methods. Results are expressed as mean ± S.E.M.
Statistical significance was assessed utilizing the paired and unpaired Student's t tests. Differences in peak glucose concentration between different glucagon dosage groups were assessed using the one-way analysis of variance. Volumes of distribution (Vd) and glucagon half-life were calculated with aid of the "C-stripping" technique of curve fitting (24) . The Vd was assumed to be stable over the range of glucagon doses utilized. Because the data best fit a two compartment pharmacokinetic model, the term half-life (t%) refers to the terminal, rather than initial t12. insulin and glucagon concentrations were also assessed. Umbilical glucose/oxygen quotients were calculated according to the formula:
This dimensionless quantity mirrors fetal glucose consumption when oxygen consumption is stable (22) . Due to limitations in blood drawing, umbilical blood flow was determined in selected experiments utilizing the antipyrine steady state diffusion technique (IS). A separate fetal venous catheter was used for antipyrine infusion.
Net umbilical. glucose uptake (Q glu) was calculated from the Fick principle: Q glu (mg/kg/min) = blood glucose venoarterial difference (mg/ml) x umbilical blood flow (ml/kg/min). Fetal weight at time of injection was estimated by extrapolation using the known birth weight of each animal at delivery or autopsy and fetal lamb growth charts. Similar calculations were made for assessment of fetal oxygen and ,B-OHB consumption or production. Fetal hematocrit, pH, pC02 and p02 (blood gases) and arterial blood pressure were determined during control and experimental periods to assure intactness of the preparations. Six neonatal lambs less than I wk of age were also studied. Femoral venous and arterial catheters were placed under local anesthesia. After a I-h recovery period serial blood samples were drawn as in the fetal experiments. Glucagon doses of 0.1 (four experiments), 0.01 (two experiments) and 0.001 (three experiments) mg/kg were utilized. In the three lambs receiving more than one injection, the doses were randomized as in the fetal experiments and were separated by recovery periods of at least 48 h.
Biochemical studies. Whole blood glucose and plasma glucose were assayed utilizing glucose oxidase techniques (22) . Whole blood oxygen content was measured with a Lex-02-Con (Lexington Instrument Corp). ,B-OHB concentration was determined en- planted. Representative data from infusion dosages of 0.1-0.5 mg/ kg were pooled as no differences existed between the glucose responses seen at these dosages over the complete 2-h postinjection period. Significant elevation of arterial and umbilical whole blood venous glucose concentrations were demonstrated at IS, 30, and 60 min postinjection. Peak glucose concentration elevations for artery and vein occurred at 30 min postinjection, reaching 10.0 ± 5.8 and 8.8 ± 5.1 mg/dl above control levels, respectively. Basal V-A glucose concentration difference was 2.88 ± 0.70 mg/dl. Postinjection values were below control at all points studied but the differences achieved statistical significance only at 30 and 90 min because of the relatively small numbers studied. At 30 min this difference was 41% of control. Small changes in arterial and umbilical venous whole blood O2 content occurred at 15,60, and 120 min but no difference was greater than 15% from control values. Basal venoarterial oxygen content difference was 1.69 ± 0.11 mM and rose by 15-25% at 15,30, and 90 min. Despite this increase the G/0 2 quotient fell to 25% of control within 15-30 min of injection (P < 0.01) and remained depressed until 120 min.
Because a limited number of injections at doses of 0.01-1.0 mg/ kg were available in these animals and because no differences in peak glucose response were noted between these doses, the data from control and 15 and 30 min postinjection were pooled (Table  2) . Again, statistically significant decrements in the venoarterial whole blood glucose difference were noted and were associated with an acute fall in the G/02 quotient. In five of these injections umbilical blood flow was measured, falling to 30% of control 2.80 ± 0.044 (9) 0.52 ± 0.07 (9) 7.22 ± 1.50 (5) 9.18 ± 0.43 (5) ships were noted between the magnitudes of insulin responses in the fetal lambs and advancing gestational age, basal fetal glucose concentration or peak glucose concentration achieved post glucagon injection. Neonatal lambs showed a brisk hyperglycemic response to the injection of all doses of glucagon utilized. Although the changes were qualitatively similar in fetal and neonatal lambs, the absolute magnitude of changes (30 min Ll plasma glucose = 61.3 ± 20.8 versus 11.7 ± 1.6 mg/dl for neonate and fetus, respectively at 0.1 mg/kg glucagon) were significantly different (P < 0.02). Similar results were apparent in the neonates when lower doses of glucagon (1-10 /lg/kg) were utilized. At I /lg/kg the peak glucose concentrations were 37.5 ± 15.5 versus 5.8 ± 1.0 mg/dl above control for neonate and fetus, respectively (P < 0.02). Neonatal plasma insulin concentrations rose in response to the injection of 0.1 mg/kg glucagon. Although the responses were qualitatively similar to the fetal responses with a peak insulin concentration achieved by 30-60 min postinjection, the magnitude of response was greater (peak Ll insulin concentration = 90 ± 36 versus 45 ± 26 /lV/ml for neonate and fetus, respectively, P < 0.05). Only a limited number of injections were performed at the lower doses (0.001-0.01 mg/kg) in the neonatal lambs. Although the absolute increments above basal were in excess of those found in the fetal lambs, the differences between fetal and neonatal lambs were not statistically significant.
Basal fetal,B-OHB concentration was 0.15 ± 0.03 mM and did not change at any dose of glucagon utilized.The data from glucagon injections of 0.01-1.0 mg/kg were, thus, pooled (Table 3) . A negligible venoarterial,B-OHB difference was detected in both control and experimental states. Neither this difference nor the 2 Significantly different (P < 0.001) from fetal control. 3 Significantly different (P < 0.05) from neonatal control.
umbilical fJ-OHB uptake was significantly different from O. Basal mean fJ-OHB concentration in the neonatal lambs studied, however was elevated 3-fold above the fetal concentration (P < 0.001).
A s~all but significant elevation in fJ-OHB level was seen 30 min after injection of 0.1 mg/kg glucagon.
DISCUSSION
Although the glycogenolytic, gluconeogenic and lipolytic actions of pancreatic glucagon in the adult are well known (5, 9, 19, 29, 32) , the role that glucagon may play in the modulation of fetal metabolism is unclear. Glucagon is present in the fetal pancreas relatively early in gestation and, like insulin, does not readily cross the placenta (27) . Although the fetal. a. cel!~esponse to adult stimuli such as alanine or hypoglycemia is mimmal, responses to arginine (2) and epineph:ine (2~) have bee~n~ted. A surge .of glucagon secretion occurs immediately after birth m several speCies including the sheep (14) and is associated with an acce~eration~f lipolysis and hepatic gluconeogenesis as well as a fall m hepatic glycogen content (3, 14, 25) , the latter suggesti~&~timulation of acute glycogenolysis. Both Girard, et al. (13) .~t~hzmg a fet~l rat model, and Schreiner and co-workers (23), utihzmg a chromcally catheterized sheep preparation similar to our own, have documented modest but significant elevations of fetal glucagon concentration after prolonged maternal fasting and have suggested that this hormone may playa role in fetal metabolic homeostasis during times of stress. The effects of isolated hyper.glucagonemia upon fetal metabolism have not been well charactenzed, however.
The chronically catheterized fetal sheep model has allowed us to study the pharmacokinetics and metabolic .effects of acute~et~l glucagon injection. The fetal glucagon half-life (tV:!) of 79 mm is longer than that found for insulin (2.3 m~) in the f~tal sheep (8) , which may be related to accelerated msulm destructiOn due to the action of placental insulinase (18) as well~s liver ,?e~iated catabolism. Glucagon extraction occurs predommant!y m liver (17) anã ppeared constant over a wide range of doses m our study. Th.is is consistent with the findings of Fisher and co-workers (12) m adult human subjects.
Injection of glucagon into the fetal lamb was associated with significant and rapid elevation of the fetal glucose concentration. Doses of 0.0 1-1.0 mg/kg of glucagon induced maximal responses by 30 min postinjection. The differences in prolongation of hyperglycemia (60--120 min) were dose dependent~nd may. have been related to the absolute glucagon concentrahons achieved. The concomitant fmdings of a depression of the glucose/oxygen quotient as well as a fall in the net umbilical glucose uptake speak for an acute increase in endogenous glucose productiOn because increased fetal glucose excretion would decrease the umbilical venoarterial glucose difference.
Some controversy exists concerning the magnitude of the fetal capacity for hepatic gluconeogenesis (3, 4) , particularly in the sheep, although it is clear that exogenous.glucagon accelerates gluconeogenesis in in vitro systems (20) . Guard and co-workers (13) have suggested that prolonged maternal fasting m~y prem~ turely induce a fetal capacity for hepatic gluconeogenesi~but thiS has not yet been substantiated. Thus, the role of chromc hyper-glucagonemia in the induction of fetal gluconeogenesis remains to be elucidated.
In view of the rapidity of the hyperglycemic response to glucagon infusion, however, an acute hepatic and, perhaps renal, glycogenolytic response to glucagon is most likely in our exp~~e~ts. The demonstration of increasing response to glucagon mJechon with advancing gestational age is also consistent with acute glucagon-stimulated glycogenolysis as liver glycogen content increases rapidly between 110 days and term in the fetal sheep (25) . Enzymes necessary for glycogen synthesis as well as degradation are also present at this stage of gestation in the fetal sheep (3) as well as in other species (26) . Increasing hepatic responsivity to glucagon, particularly with regard to hepatic adenyl cyclase activation (30) may also be important.
In the adult, hyperglucagonemia is associated with lipolysis, particularly in ruminants (5) . In addition, glucagon stimulates hepatic ketogenesis and inhibits hepatic triglyceride synthesis (21, 32) . During adaptation to fasting, lipidemia and ketonemia would serve to provide alternate energy sources, particularly to brain~I); however, in the sheep fetus exposed to prolonged maternal fastmg (22) no elevation in free fatty acids was noted and despite small elevations of ketone bodies, no significant umbilical venoarterial difference was present, suggesting minimal fetal utilization of these substrates. Hyperglucagonemia in the fetal sheep was not associated with elevation offJ-OHB concentration nor a significant increase in fetal fJ-OHB uptake or excretion. These fmdings are consistent with the view that the fetal adaptive response to maternal fasting, if modulated by glucagon, does not involve significant use of ketone as alternate substrate.
As in the adult, glucagon injection induced fetal insulin release that appeared unrelated to the hyperglycemia produced (9) . At a dose of 1.0 mg/kg glucagon, the insulin response was maximal at 60 min postinjection and had not yet fallen to control values by 120 min postinjection. It is possible that endogenously produced insulin may have blunted the pronounced hyperglycemic response seen at this dosage. Because reactive hyperinsulinemia does depress the lipolytic and ketogenic actions of.gluc~gon in ad~lt~h.eep (5) it is also possible that endogenous fetal msuhn release mhibited a rise in fJ-OHB concentration; however, the insulin increments in fetal experiments utilizing 0.1 mg/kg glucagon were relatively small, with peak values also obtained at 60 min postinjection. Because peak values obtained at the lowest doses (0.001-0.01 mg/ kg) were not statistically different from contro! ins~lin. co~centra tions, it is unlikely that endogenously released msuhn sigmficantly depressed a hyperglycemic response or inhibited ketonemia at lower doses of glucagon. Neonatal fJ-OHB concentration was significantly above the fetal level, probably the result of both dietary and hormonal influences. It is interesting that a small but significant increase in fJ-OHB concentration was noted after glucagon, in spite of relatively larger insulin response in the neonatal lamb.
In summary, the role of acute hyperglucagonemia upon fetal metabolism has been investigated. Hyperglycemia, probably secondary to acute glycogenolysis, was noted at all glucagon doses including I fLg/kg, achieving glucagon concentrations similiar to those found in states of chronic maternal fasting (23) . Although this response was quantitatively less than that of the neonate, it could conceivably be of benefit in conditions of severe substrate depletion, particularly because in this state insulin secretio~i~at a minimum (23) . Ketonemia was not noted after glucagon mJection and it is thus unlikely that endogenously elevated glucagon concentration would stimulate use of ketones as energy substrates acutely. 
